Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Urinary Bladder Carcinoma
Explore 121 assets in Urinary Bladder Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
antibody_drug_conjugate
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06305767CT.gov A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | — | Active Not Recruiting | — | — | — |
NCT05756569CT.gov Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | — | Recruiting | — | — | — |
NCT04724018CT.gov Sacituzumab Govitecan Plus EV in Metastatic UC | — | Recruiting | — | — | — |
NCT04700124CT.gov Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) (this asset) | Merck Sharp & Dohme LLC | P3 | B · 62 |
| Cis-Diamminedichloroplatinum Ii | G1 Therapeutics, Inc. | P3 | BBB |
| Trastuzumab | NKGen Biotech, Inc. | P2 | BB |
| Carboplatin | G1 Therapeutics, Inc. | P3 | BB |
| Vinblastine | University of Southern California | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Pembrolizumab | Essen Biotech | P3 | BB |
| Adriamycin | Toray Industries, Inc | P3 | BB |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
+42 more in the Urinary Bladder Carcinoma cohort
Other indications for Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urothelial Carcinoma | — | P2/3 | BB · 70 |
| Urinary Bladder Neoplasm | — | P2 | BB · 68 |
| Ureter Neoplasm | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) in Urinary Bladder Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enfortumab-vedotin-fully-human-monoclonal-antibody-conjugated-to-a-cytotoxic-agent-monomethyl-auristatin-e-mmae-targeting-nectin-4-urinary-bladder-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →